Low-molecular weight heparins in acute coronary syndromes: Theoretical background and clinical use;Eparine a basso peso molecolare e sindromi coronariche acute: Razionale teorico ed uso nella pratica clinica

Italian Heart Journal Supplement

Volumn 2, Issue 9, 2001, Pages 958-971

  Ottani, F ^a   Ferrini, D ^a   Di Pasquale, G ^a   Galvani, M ^a  

^a Ospedale di Bentivoglio   (Italy)

Author keywords

Acute coronary syndromes; Low molecular weight heparins; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ANGINA PECTORIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRACARDIAC THROMBOSIS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ANTICOAGULANTS; CHRONIC DISEASE; CLINICAL TRIALS; CORONARY DISEASE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; META-ANALYSIS; MYOCARDIAL INFARCTION; NADROPARIN;

EID: 0034759716     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Heparin
2. Low-molecular-weight heparins
3. Binding and endocytosis of heparin by human endothelial cells in culture
4. Heparin binding to plasma protein, an important mechanism for heparin resistance
5. The weight-based heparin dosing nomogram compared with "standard care" nomogram
6. Audit of control of heparin treatment
7. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
8. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
9. Guide to anticoagulant therapy. I: Heparin
10. Clotbound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors
11. Factor Xa inactivation by antithrombin 3: Evidence for biological stabilization of factor Xa by factor Vphospholipid complex
12. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
13. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin
14. Heparin-induced thrombocytopenia
15. The structure of heparin oligosaccharide fragments with high anti-factor Xa activity containing the minimal antithrombinbinding sequence
16. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin and eliciting high anti-factor Xa activity
17. The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin
18. The importance of thrombin inhibition for the expression of the anticoagulant activity of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate
19. Prolonged antithrombin activity of low-molecular weight heparin
20. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
21. Anticoagulants activities of heparin oligosaccharides and their neutralization by platelet factor 4
22. Protection of factor Xa from neutralization by heparin-antithrombin complex
23. The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma
24. The mode of action of heparin in plasma
25. Low-molecular-weight heparins; pharmacological profile and product differentiation
26. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo - Studies of venous and arterial thrombosis
27. Comparison of the pharmacokinetic profiles of three low molecular weight mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
28. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease
29. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
30. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts)
31. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
32. Partial reactivation of haemostatic mechanism after hirudin discontinuation in patients with acute coronary syndromes
33. Reactivation of unstable angina after the discontinuation of heparin
34. Low-molecular-weight heparin during instability in coronaryartery disease
35. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
36. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
37. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in ischaemic syndrome)
38. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group
39. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial
40. Adding heparin to aspirin reduces the incidences of myocardial infarction and death in patients with unstable angina
41. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI IIA
42. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction TIMI IIB-ESSENCE metaanalysis
43. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
44. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators
45. Randomized trial of low molecular weight heparin (enoxaparin) versus Linfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE study
46. A randomized trial of subcutaneous low-molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
47. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation the GUSTO IVACS randomised trial
48. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
49. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes
50. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection
51. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI IIB substudy
52. Monitoring of low-molecular-weight heparins in cardiovascular disease
53. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine
54. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Efficacy and safety of subcutaneous enoxaparin in non-q-wave coronary events (unstable angina or non-Q-wave myocardial infarction)
55. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?